Clinical laboratory · 2023
Novel Marker for Predicting Prognosis in Hepatitis B Virus-Associated Decompensated Cirrhosis: Monocyte-To-Albumin Ratio.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yuan ManChun, Mao W eiLin, He Xia, Zhang Qiu
Аннотация
BACKGROUND: Early determination of the prognosis in hepatitis B virus-associated decompensated cirrhosis (HBV-DC) patients is important to improve their survival. The present study aimed to determine the predictive ability of monocyte-to-albumin ratio (MAR) for poor prognosis in HBV-DC.
METHODS: This work recruited 263 HBV-DC patients admitted to our hospital from November 2020 through March 2022. The clinical data, laboratory parameters, and clinical prognosis of the patients were retrospectively collected and analyzed.
RESULTS: Mortality at 30 days was 20.2% (53/263). MAR was found to be higher in the non-survivors compared with the survivors. Higher MAR was associated with higher 30-day mortality, and MAR was identified as an independent predictor of poor prognosis in HBV-DC. Furthermore, the predictive values between MAR and Model for End-Stage Liver Disease score are comparable.
CONCLUSIONS: MAR could be potentially used as a novel prognostic marker to predict prognosis in HBV-DC.
METHODS: This work recruited 263 HBV-DC patients admitted to our hospital from November 2020 through March 2022. The clinical data, laboratory parameters, and clinical prognosis of the patients were retrospectively collected and analyzed.
RESULTS: Mortality at 30 days was 20.2% (53/263). MAR was found to be higher in the non-survivors compared with the survivors. Higher MAR was associated with higher 30-day mortality, and MAR was identified as an independent predictor of poor prognosis in HBV-DC. Furthermore, the predictive values between MAR and Model for End-Stage Liver Disease score are comparable.
CONCLUSIONS: MAR could be potentially used as a novel prognostic marker to predict prognosis in HBV-DC.